Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Status:
Active, not recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Phase II, single-arm, open-label multicenter study that assesses feasibility, safety and
efficacy of combined neoadjuvant chemotherapy and immunotherapy with Nivolumab 360 mg IV Q3W
+ Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult
patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months
and Nivolumab 480mg Q4W for 8 months.